2022 -- H 7503 SUBSTITUTE A

LC004745/SUB A

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

STATE OF RHODE ISLAND

IN GENERAL ASSEMBLY

JANUARY SESSION, A.D. 2022

AN ACT

RELATING TO INSURANCE -- ACCIDENT AND SICKNESS INSURANCE POLICIES

Introduced By: Representatives Amore, and Henries

Date Introduced: February 16, 2022

Referred To: House Health & Human Services

It is enacted by the General Assembly as follows:

neuropsychiatric syndrome.

SECTION 1. Chapter 27-18 of the General Laws entitled "Accident and Sickness Insurance
Policies" is hereby amended by adding thereto the following section:

27-18-89. Mandatory coverage for treatment of pediatric autoimmune
neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset

(a) Every group health insurance contract, or every group hospital or medical expense insurance policy, plan, or group policy delivered, issued for delivery, or renewed in this state, by any health insurance carrier, on or after January 1, 2023, shall provide coverage for treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome, including, but not limited to, the use of intravenous immunoglobin therapy.

(b) For billing and diagnosis purposes, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome shall be coded as autoimmune encephalitis until the American Medical Association and the Centers for Medicare and Medicaid Services create and assign a specific code for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome. Thereafter, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome may be coded as autoimmune encephalitis, pediatric autoimmune neuropsychiatric disorders associated

2	(c) The health care benefits outlined in this section apply only to services delivered within
3	the state of Rhode Island; provided, that all health insurance carriers shall be required to provide
4	coverage for those benefits mandated by this section outside of the state of Rhode Island where it
5	can be established through a pre-authorization process that the required services are not available
6	in the state of Rhode Island from a provider in the health insurance carrier's network.
7	SECTION 2. Chapter 27-19 of the General Laws entitled "Nonprofit Hospital Service
8	Corporations" is hereby amended by adding thereto the following section:
9	27-19-81. Mandatory coverage for treatment of pediatric autoimmune
10	neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset
11	neuropsychiatric syndrome.
12	(a) Every group health insurance contract, or every group hospital or medical expense
13	insurance policy, plan, or group policy delivered, issued for delivery, or renewed in this state, by
14	any health insurance carrier, on or after January 1, 2023, shall provide coverage for treatment of
15	pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and
16	pediatric acute onset neuropsychiatric syndrome, including, but not limited to, the use of
17	intravenous immunoglobin therapy.
18	(b) For billing and diagnosis purposes, pediatric autoimmune neuropsychiatric disorders
19	associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome shall
20	be coded as autoimmune encephalitis until the American Medical Association and the Centers for
21	Medicare and Medicaid Services create and assign a specific code for pediatric autoimmune
22	neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset
23	neuropsychiatric syndrome. Thereafter, pediatric autoimmune neuropsychiatric disorders
24	associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome may
25	be coded as autoimmune encephalitis, pediatric autoimmune neuropsychiatric disorders associated
26	with streptococcal infections, or pediatric acute onset neuropsychiatric syndrome.
27	(c) The health care benefits outlined in this section apply only to services delivered within
28	the state of Rhode Island; provided, that all health insurance carriers shall be required to provide
29	coverage for those benefits mandated by this section outside of the state of Rhode Island where it
30	can be established through a pre-authorization process that the required services are not available
31	in the state of Rhode Island from a provider in the health insurance carrier's network.
32	(d) Each health insurance carrier shall collect and provide to the office of the health
33	insurance commissioner, in a form and frequency acceptable to the commissioner, information and
34	data reflecting the costs and the savings of adding the benefit coverage provided in this section. On

with streptococcal infections, or pediatric acute onset neuropsychiatric syndrome.

1

1	or before January 1, 2025, the office of the health insurance commissioner shall report to the general
2	assembly a cost-benefit analysis of the implementation of the benefit coverage provided in this
3	section. The intent of this cost-benefit analysis is to determine if adding the benefit coverage
4	provided in this section produces a net savings to health insurance carriers and to policy holders.
5	(e) This section shall sunset and be repealed effective December 31, 2025.
6	SECTION 3. Chapter 27-20 of the General Laws entitled "Nonprofit Medical Service
7	Corporations" is hereby amended by adding thereto the following section:
8	27-20-77. Mandatory coverage for treatment of pediatric autoimmune
9	neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset
10	neuropsychiatric syndrome.
11	(a) Every group health insurance contract, or every group hospital or medical expense
12	insurance policy, plan, or group policy delivered, issued for delivery, or renewed in this state, by
13	any health insurance carrier, on or after January 1, 2023, shall provide coverage for treatment of
14	pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and
15	pediatric acute onset neuropsychiatric syndrome, including, but not limited to, the use of
16	intravenous immunoglobin therapy.
17	(b) For billing and diagnosis purposes, pediatric autoimmune neuropsychiatric disorders
18	associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome shall
19	be coded as autoimmune encephalitis until the American Medical Association and the Centers for
20	Medicare and Medicaid Services create and assign a specific code for pediatric autoimmune
21	neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset
22	neuropsychiatric syndrome. Thereafter, pediatric autoimmune neuropsychiatric disorders
23	associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome may
24	be coded as autoimmune encephalitis, pediatric autoimmune neuropsychiatric disorders associated
25	with streptococcal infections, or pediatric acute onset neuropsychiatric syndrome.
26	(c) The health care benefits outlined in this section apply only to services delivered within
27	the state of Rhode Island; provided, that all health insurance carriers shall be required to provide
28	coverage for those benefits mandated by this section outside of the state of Rhode Island where it
29	can be established through a pre-authorization process that the required services are not available
30	in the state of Rhode Island from a provider in the health insurance carrier's network.
31	(d) Each health insurance carrier shall collect and provide to the office of the health
32	insurance commissioner, in a form and frequency acceptable to the commissioner, information and
33	data reflecting the costs and the savings of adding the benefit coverage provided in this section. On
34	or before January 1, 2025, the office of the health insurance commissioner shall report to the general

1	assembly a cost-benefit analysis of the implementation of the benefit coverage provided in this
2	section. The intent of this cost-benefit analysis is to determine if adding the benefit coverage
3	provided in this section produces a net savings to health insurance carriers and to policy holders.
4	(e) This section shall sunset and be repealed effective December 31, 2025.
5	SECTION 4. Chapter 27-41 of the General Laws entitled "Health Maintenance
6	Organizations" is hereby amended by adding thereto the following section:
7	27-41-94. Mandatory coverage for treatment of pediatric autoimmune
8	neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset
9	neuropsychiatric syndrome.
10	(a) Every group health insurance contract, or every group hospital or medical expense
11	insurance policy, plan, or group policy delivered, issued for delivery, or renewed in this state, by
12	any health insurance carrier, on or after January 1, 2023, shall provide coverage for treatment of
13	pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and
14	pediatric acute onset neuropsychiatric syndrome, including, but not limited to, the use of
15	intravenous immunoglobin therapy.
16	(b) For billing and diagnosis purposes, pediatric autoimmune neuropsychiatric disorders
17	associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome shall
18	be coded as autoimmune encephalitis until the American Medical Association and the Centers for
19	Medicare and Medicaid Services create and assign a specific code for pediatric autoimmune
20	neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset
21	neuropsychiatric syndrome. Thereafter, pediatric autoimmune neuropsychiatric disorders
22	associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome may
23	be coded as autoimmune encephalitis, pediatric autoimmune neuropsychiatric disorders associated
24	with streptococcal infections, or pediatric acute onset neuropsychiatric syndrome.
25	(c) The health care benefits outlined in this section apply only to services delivered within
26	the state of Rhode Island; provided, that all health insurance carriers shall be required to provide
27	coverage for those benefits mandated by this section outside of the state of Rhode Island where it
28	can be established through a pre-authorization process that the required services are not available
29	in the state of Rhode Island from a provider in the health insurance carrier's network.
30	(d) Each health insurance carrier shall collect and provide to the office of the health
31	insurance commissioner, in a form and frequency acceptable to the commissioner, information and
32	data reflecting the costs and the savings of adding the benefit coverage provided in this section. On
33	or before January 1, 2025, the office of the health insurance commissioner shall report to the general
34	assembly a cost-benefit analysis of the implementation of the benefit coverage provided in this

- 1 section. The intent of this cost-benefit analysis is to determine if adding the benefit coverage
- 2 provided in this section produces a net savings to health insurance carriers and to policy holders.
- 3 (e) This section shall sunset and be repealed effective December 31, 2025.
- 4 SECTION 5. This act shall take effect upon passage.

====== LC004745/SUB A

EXPLANATION

BY THE LEGISLATIVE COUNCIL

OF

AN ACT

RELATING TO INSURANCE -- ACCIDENT AND SICKNESS INSURANCE POLICIES

- This act would require coverage for the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome, including, but not limited to, the use of intravenous immunoglobin therapy.

 This act would take effect upon passage.

LC004745/SUB A
